Background
Leukotriene receptor antagonists are a new class of drug that were initially identified for use in asthma. As they have an effect on neutrophil mediated inflammation, they may be of benefit in bronchiectasis. 
Objectives
To determine whether leukotriene receptor antagonists have any additive benefit over and above conventional treatment for bronchiectasis (usually consisting of antibiotics and postural drainage). 
Search methods
The Cochrane Airways Group Specialised Regsiter of trials and CENTRAL were searched up to May 2011. 
Selection criteria
Only randomised, controlled trials were considered
Data collection and analysis
The results of searches were analysed by both authors
Main results
No randomised, controlled trials were identified. The latest search was in May 2011.
Authors' conclusions
Further research is required to establish any benefit from the use of leukotriene antagonists in bronchiectasis. 
